Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance|
|Citation:||British Journal of Cancer, 2013; 109(6):1593-1598|
|Publisher:||Nature Publishing Group|
|W T Parker, A L Yeoman, B A Jamison, D T Yeung, H S Scott, T P Hughes, and S Branford|
|Abstract:||BACKGROUND: BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated. METHODS: We examined longitudinal data of patients with imatinib-resistant mutations, which became undetectable by Sanger sequencing to determine whether mutations could reappear, and the related circumstances. RESULTS: Identical imatinib- and nilotinib-resistant mutations reappeared following further therapy changes in five patients, and was associated with subsequent nilotinib resistance in four. CONCLUSION: The data suggest that some BCR-ABL1 mutations may persist at undetectable levels for many years after changing therapy, and can be reselected and confer resistance to subsequent inhibitors.|
|Keywords:||chronic myeloid leukaemia; mutation analysis; tyrosine kinase inhibitor; resistance|
|Rights:||© 2013 Cancer Research UK. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.